Medtronic Warms To Cryoablation With $380 Million Acquisition Of CryoCath
This article was originally published in The Gray Sheet
Executive Summary
Medtronic gains a stake in the race to get the first FDA approval of an ablation catheter for atrial fibrillation with its $380 million acquisition of Montreal-based CryoCath, announced Sept. 25
You may also be interested in...
Medtronic’s Hawkins To Retire; Company Sets External Search For New CEO
Medtronic Chairman and CEO William Hawkins is retiring after just three years in the firm’s top spot, a move that may reflect the company’s desire to accelerate change and diversification in the face of sluggish growth in signature businesses.
Medtronic’s Hawkins To Retire; Company Sets External Search For New CEO
Medtronic Chairman and CEO William Hawkins is retiring after just three years in the firm’s top spot, a move that may reflect the company’s desire to accelerate change and diversification in the face of sluggish growth in signature businesses.
Medtronic STOP AF Results Show Efficacy, But Raise Some Safety Concerns
Results of Medtronic's STOP AF trial show that 69.3% of patients treated with its Arctic Front cryoballoon catheter were free from atrial fibrillation at one year